04.07.2019 • News

Gelest Boosts Portfolio with Bimax Buy

Gelest Boosts Portfolio with Bimax Buy
Gelest Boosts Portfolio with Bimax Buy

Gelest, a US manufacturer of silicones, organosilanes and metal-organics, has purchased Bimax, a producer of specialty monomers and polymers used to make contact and intraocular lenses, personal care products, coatings and adhesives, among other advanced technology applications. Financial terms of the deal were not disclosed.

Commenting on the acquisition, Ken Gayer, Gelest’s CEO, said:  “Bimax strengthens our position in high-growth value-added applications, provides access to new customers and talent and expands our production capability and R&D pipeline.”

Andre Moura, managing director at Gelest’s majority shareholder New Mountain Capital, added that the two businesses were highly complementary.

Gelest has been a portfolio company of New York-based investment firm New Mountain Capital since March 2017. New Mountain Capital owns a controlling interest in the Morrisville, Pennsylvania-based company, with Gelest’s founder and management team maintaining a “significant” shareholding.

Bimax, which is headquartered in Glen Rock, Pennsylvania, will continue to operate under its own name and will retain all its employees in their current roles.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read